Biohit Oyj
Biohit Oyj and Akeso to sign an Acetium distribution agreement in Russia
DGAP-News: Biohit Oyj 2015-02-17 / 12:00 --------------------------------------------------------------------- Biohit Oyj Biohit Oyj Press Release February 17, 2015 at 1:00 p.m. local time (EET) Biohit Oyj has signed a distribution agreement with Akeso Pharmaceuticals. The agreement is effective immediately and Akeso gains exclusive rights for the distribution of Acetium(R) capsules in Russian Federation. Acetium capsules efficiently bind (neutralize) carcinogenic acetaldehyde in an achlorhydric stomach. This contributes to the prevention of cancer in the mouth, stomach and oesophagus. Acetium capsules are intended e.g. for PPI users and persons suffering from an achlorhydric stomach caused by atrophy of the gastric mucosa and functional disorder (atrophic gastritis). An anacidic stomach is the most significant risk factor for stomach and oesophageal cancer (1). Clinical trials with Acetium(R) capsule for prevention of migraine-type headache and the treatment of atrophic gastritis are ongoing. CEO Semi Korpela, Biohit Oyj: 'We are pleased to partner with Akeso Pharmaceuticals in order to introduce acetaldehyde binding capsules to the Russian markets as soon as the registration procedures are completed.' Managing Director Imran Mir, Akeso Pharmaceuticals: 'We are very glad to have the opportunity to start business with the highly-talented Biohit team. I'm sure that together we will be successful in introducing Biohit's innovative and valuable products into Russian market. ' Reference: (1) Sipponen P et al (1985) Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173-177. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Attachment: Additional information Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is 'Innovating for Health' - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com Akeso in brief Akeso is a pharmaceutical company marketing and distributing anti TB, anti infectious and anti cancer drugs in Russian Federation. We provide wide range of different services and supply products for healthcare by establishing and maintaining effective cooperation with the specialized agencies, governmental health organizations, professional groups, and other organizations as may be deemed appropriate. www.akeso.ru News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-02-17 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Biohit Oyj Finland ISIN: FI0009005482 End of News DGAP News-Service --------------------------------------------------------------------- 324143 2015-02-17
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden